Inventor · disambiguated record
Terry J. Fry
Also filed as: FRY TERRY · FRY TERRY J · FRY TERRY JAMES
13 granted patents·13 pending applications·11 citations·filing 2014–2024
86Inventor score
Top patents by PatentIndex Score
26 records- 0188US11802157B2Methods and compositions for modulating CAR-T activitySANA BIOTECHNOLOGY INC·Filed 2022·Granted Oct 31, 2023·1 cites·27 claims
- 0287US12202902B2FLT3-specific chimeric antigen receptors and methods using sameUS HEALTH·Filed 2022·Granted Jan 21, 2025·1 cites·19 claims
- 0387US11980640B2Bicistronic chimeric antigen receptors and their usesUS HEALTH·Filed 2018·Granted May 14, 2024·3 cites·20 claims
- 0484US10738116B2Dual specific anti-CD22-anti-CD19 chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES·Filed 2016·Granted Aug 11, 2020·3 cites·24 claims
- 0582US11299546B2FLT3-specific chimeric antigen receptors and methods using sameUS HEALTH·Filed 2017·Granted Apr 12, 2022·2 cites·20 claims
- 0680US11987628B2Methods and compositions for modulating CAR-T activitySANA BIOTECHNOLOGY INC·Filed 2023·Granted May 21, 2024·0 cites·30 claims
- 0780US2025019433A1Methods and compositions for modulating car-t activitySANA BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 0878US2025034244A1Bicistronic chimeric antigen receptors and their usesUS HEALTH·Filed 2024·Application pending·0 cites
- 0975US11965022B2Methods and compositions for modulating CAR-T activitySANA BIOTECHNOLOGY INC·Filed 2021·Granted Apr 23, 2024·0 cites·20 claims
- 1074US12012455B2Human monoclonal antibodies specific for FLT3 and uses thereofUS HEALTH·Filed 2022·Granted Jun 18, 2024·0 cites·20 claims
- 1172US10676528B2Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using sameUS HEALTH·Filed 2014·Granted Jun 9, 2020·1 cites·22 claims
- 1270US11497770B2Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Nov 15, 2022·0 cites·5 claims
- 1370US2023256020A1Compositions and Methods for Treating Cancer with TSLPR-CD19 or TSLPR-CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 1466US2025304913A1Chimeric antigen receptor t cells and methods of use thereofUNIV COLORADO REGENTS·Filed 2023·Application pending·0 cites
- 1566US2025177447A1Gprc5d-specific antibody constructs and compositions thereofSANA BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 1664US2025082777A1Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and usesSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1763US11236171B2Human monoclonal antibodies specific for FLT3 and uses thereofUS HEALTH·Filed 2017·Granted Feb 1, 2022·0 cites·26 claims
- 1862US11834509B2Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using sameUS HEALTH·Filed 2020·Granted Dec 5, 2023·0 cites·22 claims
- 1962US2025313861A1Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methodsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2061US11939377B2Affinity matured CD22-specific monoclonal antibody and uses thereofUS HEALTH·Filed 2019·Granted Mar 26, 2024·0 cites·35 claims
- 2161US2025302953A1Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cellsSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 2259US2025302876A1Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methodsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2353US2023174614A1Multispecific anti-flt3 chimeric antigen receptorsFRY TERRY J·Filed 2021·Application pending·0 cites
- 2452US2025114452A1Lat activating chimeric antigen receptor t cells and methods of use thereofUNIV COLORADO REGENTS·Filed 2022·Application pending·0 cites
- 2548US2024390419A1Cd3 epsilon chimeric antigen receptors and methods of use thereofUNIV COLORADO REGENTS·Filed 2022·Application pending·0 cites
- 2645US2021017277A1Anti-cd33 chimeric antigen receptors and their usesUS HEALTH·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →